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Vasculitis is a well recognised complication of Cystic Fibrosis. Corticosteroids are the mainstay of treatment but some cases can be resistant
and may require additional disease modifying agents.
We describe a case of steroid resistant cutaneous vasculitis which was successfully treated with chloroquine in addition to corticosteroids and a
subsequent relapse with chloroquine alone.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Vasculitis is an unusual complication of cystic fibrosis (CF),
normally affecting patients with more severe lung disease.
Typical presentation is with skin disease but other organ
involvement has been reported [1,2].
We describe a case of vasculitis in a patient with CF, with
typical skin purpura reoccurring shortly after surgical resection
of an ileocaecal intussusception, and its successful treatment
with chloroquine in addition to corticosteroids and subsequently
with chloroquine alone.1. Case history
The patient is a 28 year old male ΔF508 homozygote with
well controlled lung disease prior to the vasculitic episodes
(FEV1 3.2L; 75% predicted). He has insulin treated diabetes
and a long standing history of seronegative inflammatory
arthritis primarily affecting the small joints of the hands and
feet. His joint disease was stable on sulphasalazine for more
than 10 years. Antinuclear factor was negative.
He initially developed a purpuric rash on the lower limbs in
association with an exacerbation of his lung disease which
resolved over a period of 5 weeks. A course of intravenous⁎ Corresponding author. Tel.: +44 01482624067; fax: +44 01482624068.
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doi:10.1016/j.jcf.2010.08.017antibiotics was given but no active treatment was necessary for
the purpura.
He was subsequently admitted to hospital with a putative
diagnosis of Distal Intestinal Obstruction Syndrome. Imaging
was consistent with obstruction secondary to ileocaecal
intussusception and he underwent a right hemicolectomy after
the failure of conservative treatment with gastrograffin. A
polypoid lesion found at the apex of the intussusception post-
resection consisted of inflamed and oedematous ileal mucosa.
Six weeks later, he was readmitted with a recurrence of the
purpura on both lower limbs (Fig. 1) and on the posterior
aspects of both arms. On this occasion there was no
deterioration in respiratory symptoms. Renal function was
normal throughout.
Sulphasalazine was withdrawn as a drug reaction was
suspected and treatment was commenced with oral predniso-
lone 60 mg daily. Skin biopsy was performed during incidental
surgical insertion of a totally implantable venous access device
which showed abundant neutrophils within the dermis with
evidence of leucocytoclasis. No eosinophilic infiltrate was seen
in the biopsy. Antineutrophil cytoplasmic antibody (ANCA)
screen was reported as atypical with negative MPO and PR3
antibodies.
He was discharged from the hospital after 5 days. There was
no noticeable improvement after 7 days of steroid therapy
(Figs. 2 and 3). Chloroquine was suggested as a potentiald by Elsevier B.V. All rights reserved.
Fig. 1. Appearance of purpura on the lower limbs at presentation.
Fig 3. Proximal extent of the rash on the right lower limb.
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250 mg b.d. for 1 week. Oral prednisolone was continued at the
same dose. The rash improved rapidly after initiation of
chloroquine and had resolved completely at 3 weeks after
presentation. Fig. 4 is an image taken on day 3 of combined
treatment.
The patient had a further relapse of cutaneous vasculitis after
4 months which was successfully treated with chloroquine
alone using the same regimen. On this occasion, chloroquine
was commenced 4 days after the appearance of the rash and
complete resolution was achieved within 2 weeks of starting
treatment. He was not taking sulphasalazine at the time of the
second relapse and it has since been re-introduced in response to
a deterioration in his joint disease with no adverse effects.
2. Discussion
Vasculitis is a well documented complication of CF [1].
Suggested mechanisms include systemic response to bacterial
colonization and immune complex deposition secondary to
chronic airway inflammation [2–4]. There is also an associationFig. 2. Appearance after 5 days of corticosteroid therapy.between joint disease in CF and vasculitis [5,6]. Typical
presentation is with a purpuric rash affecting the lower limbs
with classical histological findings of a leucocytoclastic
vasculitis [2,7].
ANCA positivity is common in CF and although MPO and
PR3 specificity can be found, antibodies are often directed
against bactericidal/permeability increasing protein (BPI), a
neutrophil product which has antimicrobial action against
Pseudomonas aeruginosa [8,9]. The presence of anti-BPI is
associated with pseudomonal colonisation and increased
severity of lung disease [10,11]. Although it was not
specifically identified in the patient described, anti-BPI is aFig 4. Day 3 of combination therapy with prednisolone and chloroquine.
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vasculitis and has a higher prevalence in CF patients with
vasculitis than those without [12,13].
Cutaneous vasculitis can be associated with sulphasalazine
therapy however the clinical features in this case do not support
a drug-induced aetiology [14,15]. There was no eosinophilic
infiltrate seen in the skin biopsy, the second relapse occurred
several months after stopping treatment and the agent was later
re-introduced without complication.
The colonic intussusception was not confirmed histological-
ly to have a vasculitic origin as the changes seen were felt to be
reactive rather than causal, although the temporal association of
the events could suggest that the two were related. Ileocaecal
intussusception is a recognised complication of CF and an
association with henoch–schönlein purpura (HSP) has also
previously been reported [16,17]. HSP was initially considered
as an alternative diagnosis as it can also manifest with an IgA
mediated leucocytoclastic vasculitis. Immunofluorescence was
not performed but the age of the patient and the absence of renal
involvement and arthralgia meant that he did not meet the
diagnostic criteria [18,19].
CF associated vasculitis can resolve spontaneously however
where there is a need for treatment, corticosteroids have been
used and there has been a previous case reported of successful
treatment using methotrexate [1,2,20]. Chloroquine is used as
an antimalarial and as a disease modifying agent in rheumatoid
arthritis and lupus erythematosus [21,22]. Its mechanism of
action is not clearly understood but may involve reduced
eicosanoid production via inhibition of phospholipase A2 or
interference with proinflammatory cytokines [23]. It was chosen
on the basis of clinical experience of its use and minimal side
effect profile. We found no previous reports in the literature of
cases where chloroquine has been successfully used to treat CF
associated vasculitis. In this case, there was a dramatic
improvement in the appearance of the rash when chloroquine
was added to corticosteroids. Resolution occurred more quickly
in the relapses treated with combination therapy and with
chloroquine alone than in the initial self-limiting episode. The
patient suffered no adverse effects from either treatment.
There is insufficient evidence to advocate the routine use of
chloroquine monotherapy in CF associated vasculitis. Corti-
costeroids remain the first choice but chloroquine may be useful
as an adjunct in steroid resistant cases.
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